Wenger Plattner advises Bachem on concluding a strategic collaboration agreement with Eli Lilly

On April 26, 2022, Bachem (SIX: BANB) announced the conclusion of a strategic collaboration with Eli Lilly and Company regarding the development and manufacture of pharmaceutical active ingredients from oligonucleotides, a new class of complex molecules. As part of this collaboration, Bachem will support the application of Lilly’s new oligonucleotide manufacturing technology by providing technical infrastructure and expertise, as well as research and production capacity for the development and manufacture of GMP-quality active ingredients for Lilly’s investigational drugs based on oligonucleotides. The manufacturing volume for Lilly extends over a period of 7 years, with an annual order volume potential of around CHF 100 million.
 

Wenger Plattner (Dr. Tobias Meili) supported Bachem in negotiating the collaboration agreement as well as aspects of the SIX listing regulations.